Reducing intellectual property protection for biologic drugs and further cutting Medicare Part B reimbursements would suppress access to needed drugs and weaken community caregivers, writes Peter Pitts, president of the Center for Medicine in the Public Interest and a former associate commissioner at the FDA. Part B's reimbursement formula is helping to curb long-term health care costs and guarantees access to necessary treatments, Pitts writes.

Full Story:

Related Summaries